Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Altimmune (NASDAQ:ALT) issued its earnings results on Tuesday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03, Zacks reports. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 52.60%. The firm had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the firm posted ($0.39) EPS.

Altimmune Trading Up 0.3 %

Shares of ALT stock opened at $9.52 on Thursday. The company has a market capitalization of $676.59 million, a P/E ratio of -6.14 and a beta of 0.09. The business’s 50 day moving average is $6.95 and its two-hundred day moving average is $6.89. Altimmune has a twelve month low of $2.34 and a twelve month high of $14.84.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. UBS Group initiated coverage on Altimmune in a research report on Tuesday. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, B. Riley reissued a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Insiders Place Their Bets

In other news, Director David Drutz sold 16,011 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.10% of the stock is owned by insiders.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.